Be the first to review this item
Vazaprostan is a preparation of prostaglandin E1. Improves microcirculation and peripheral circulation.
Reduces the tone of arterioles and postcapillary sphincters, reduces OPSS without changing blood pressure, increases coronary blood flow and the fraction of left ventricular ejection.
Improves the rheological properties of blood by reducing adhesion and aggregation of platelets, reducing aggregation and improving the deformability of erythrocytes, increasing fibrinolytic activity and reducing blood viscosity.
It has an effect on metabolism, increases the utilization of glucose and oxygen, inhibits the release of free radicals and lysosomal enzymes from granulocytes and macrophages, stimulates the synthesis of proteins, has a beneficial effect on lipid metabolism (suppression of cholesterol synthesis and decrease in LDL concentration), inhibits the proliferation and mitosis of smooth muscle cells.
Against the backdrop of treatment, Vasaprostan decreases the severity of the pain syndrome at rest, accelerates the healing of trophic ulcers, and a remission occurs during the course of the disease.
Treatment of chronic obliterating diseases of arteries of III and IV stages.
Vasaprostan can be administered in / a and / in.
To obtain a solution for intra-arterial administration, 20 μg (the contents of one ampoule) should be dissolved in 50 ml of saline. When carrying out the intravenous infusion, 25 ml of the resulting solution (10 μg alprostadil) should be administered within 60-120 minutes using a special device for intravenous infusion. If necessary (especially with necrosis), the dose can be increased to 50 ml (20 μg). If the drug is administered through an established catheter, the infusion is administered for 12 hours at a dose of 0.1-0.6 ng / kg body weight per minute (corresponding to 12.5-25 ml of a solution of Vasaprostan).
To obtain a solution for intravenous administration, 40 μg (the contents of two ampoules) of dry matter should be dissolved in 50-250 ml of physiological solution and injected solution in / in the drip for 2 hours 2 times / day, or dissolve 60 μg (the contents of 3 ampoules) in 50-250 ml of physiological solution and injected / drip for 3 hours 1 time / day.
In patients with impaired renal function (creatinine concentration more than 1.5 mg / dl) IV injection of Vazaprostan should be started with 10 mg 2 times / day, the duration of each infusion is 2 hours. With good tolerability for 2-3 days, the dose can be increased to usual. The duration of one course of treatment should not exceed 4 weeks.
From the cardiovascular system: palpitation, arterial hypotension, headache; in a few cases - increased rates of angina pectoris, the development of pulmonary edema, the phenomena of heart failure.
From the digestive system: dyspeptic phenomena, increased activity of hepatic transaminases.
Other: leukopenia, leukocytosis; with prolonged therapy (more than 4 weeks) in isolated cases, hyperostosis of tubular bones.
Local reactions: edema, hyperemia, pain at the injection site.
During treatment with Vasaprostan, patients with signs of renal and heart failure should be limited to a volume of 50-100 ml / day.
In the course of therapy should monitor blood pressure, heart rate, if necessary - control fluid balance, measurement of central venous pressure, Echocardiography. Clinical efficacy of treatment is evaluated after 3 weeks of therapy.
On the background of therapy with vasaprostane, the appearance of a C-reactive protein can be observed in the biochemical study of blood.
Important notice- the outer box design may vary before prior notice!
Someone from the France - just purchased the goods:
Betoftan eye drops 0.5% 5ml